Patients with moderate plaque psoriasis, who were naïve to systemic biologic therapy, showed significantly improved skin clearance when treated with the oral, selective inhibitor of phosphodiesterase 4 (PDE4) apremilast (Otezla; Celgene Corp), according to results presented at the 2017 American Academy of Dermatology Annual Meeting in Orlando, FL.
The phase 4 Unveil trial evaluated the clinical efficacy of apremilast 30mg twice daily compared with placebo at week 16 in 221 patients. At the meeting, the researchers reported greater improvement in mean percentage change from baseline in Physician’s Global Assessment (PGA) and body surface area (BSA) compared to placebo (P<0.0001) at week 16. Additionally, researchers observed a 75% or greater improvement in both PGA and BSA score in 35.1% of patients treated with apremilast, compared to 12.3% of patients treated with placebo (P<0.0001). A larger percentage of patients receiving apremilast versus placebo achieved a PGA score of 0 (clear) or 1 (almost clear) at week 16 (P<0.0001).
Enrolled patients who had scalp psoriasis (n=167) and who received apremilast showed a significantly greater percentage of improvement. They achieved a Scalp Physician’s Global Assessment score of 0 (clear) or 1 (minimal) with a greater than 2-point reduction from baseline compared with placebo (P=0.0178).
Adverse events were reported in both the apremilast and placebo groups and included diarrhea (29% and 16%), headache (20% and 11%), nausea (18% and 10 percent), upper respiratory tract infection (7% and 4%) and vomiting (6% and 3%).
Patients with moderate plaque psoriasis, who were naïve to systemic biologic therapy, showed significantly improved skin clearance when treated with the oral, selective inhibitor of phosphodiesterase 4 (PDE4) apremilast (Otezla; Celgene Corp), according to results presented at the 2017 American Academy of Dermatology Annual Meeting in Orlando, FL.
The phase 4 Unveil trial evaluated the clinical efficacy of apremilast 30mg twice daily compared with placebo at week 16 in 221 patients. At the meeting, the researchers reported greater improvement in mean percentage change from baseline in Physician’s Global Assessment (PGA) and body surface area (BSA) compared to placebo (P<0.0001) at week 16. Additionally, researchers observed a 75% or greater improvement in both PGA and BSA score in 35.1% of patients treated with apremilast, compared to 12.3% of patients treated with placebo (P<0.0001). A larger percentage of patients receiving apremilast versus placebo achieved a PGA score of 0 (clear) or 1 (almost clear) at week 16 (P<0.0001).
Enrolled patients who had scalp psoriasis (n=167) and who received apremilast showed a significantly greater percentage of improvement. They achieved a Scalp Physician’s Global Assessment score of 0 (clear) or 1 (minimal) with a greater than 2-point reduction from baseline compared with placebo (P=0.0178).
Adverse events were reported in both the apremilast and placebo groups and included diarrhea (29% and 16%), headache (20% and 11%), nausea (18% and 10 percent), upper respiratory tract infection (7% and 4%) and vomiting (6% and 3%).
Patients with moderate plaque psoriasis, who were naïve to systemic biologic therapy, showed significantly improved skin clearance when treated with the oral, selective inhibitor of phosphodiesterase 4 (PDE4) apremilast (Otezla; Celgene Corp), according to results presented at the 2017 American Academy of Dermatology Annual Meeting in Orlando, FL.
The phase 4 Unveil trial evaluated the clinical efficacy of apremilast 30mg twice daily compared with placebo at week 16 in 221 patients. At the meeting, the researchers reported greater improvement in mean percentage change from baseline in Physician’s Global Assessment (PGA) and body surface area (BSA) compared to placebo (P<0.0001) at week 16. Additionally, researchers observed a 75% or greater improvement in both PGA and BSA score in 35.1% of patients treated with apremilast, compared to 12.3% of patients treated with placebo (P<0.0001). A larger percentage of patients receiving apremilast versus placebo achieved a PGA score of 0 (clear) or 1 (almost clear) at week 16 (P<0.0001).
Enrolled patients who had scalp psoriasis (n=167) and who received apremilast showed a significantly greater percentage of improvement. They achieved a Scalp Physician’s Global Assessment score of 0 (clear) or 1 (minimal) with a greater than 2-point reduction from baseline compared with placebo (P=0.0178).
Adverse events were reported in both the apremilast and placebo groups and included diarrhea (29% and 16%), headache (20% and 11%), nausea (18% and 10 percent), upper respiratory tract infection (7% and 4%) and vomiting (6% and 3%).
